Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

This study is testing whether adding an immunotherapy drug (serplulimab) to chemotherapy before surgery can improve outcomes for people with limited-stage small cell lung cancer — a fast-growing type of lung cancer that has not yet spread widely. **You may be eligible if...** - You are 18–75 years old - You have small cell lung cancer confirmed by biopsy, at stage IIB–IIIB (limited stage) - You have not had any prior treatment for lung cancer - Surgeons have determined you are a candidate for surgery - Your overall health and organ function meet the study requirements - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have had prior chemotherapy, radiation, or surgery for lung cancer - You have active or poorly controlled hepatitis B or C infection - You are pregnant or planning to become pregnant without using contraception Talk to your doctor to see if this trial is right for you.